IHE Report / IHE Rapport,
IHE - The Swedish Institute for Health Economics

Abstract: Cost-effectiveness analysis involves calculating the incremental cost per quality-adjusted life year (QALY) gained. The maximum acceptable cost per QALY is commonly referred to as the threshold value. The threshold value thus provides an indication of what is considered acceptable by the authority or organization responsible for assessing the value of the new medical technology.

This report provides an overview of the threshold value, what it is, how it can be estimated, and the questions it is intended to answer. The threshold value is closely linked to the principles of value-based pricing (VBP) that we use in Sweden.

The report proposes raising the TLV’s threshold values from an average of approximately 870,000 SEK to 1.3 million SEK for innovative patented medicines.

Keywords: QALY; threshold value; value based pricing; tröskelvärde; värde av hälsa; Preferenser och värdering.Preferences and valuation; metod; method; Ekonomisk utvärdering; Economic evaluation

Language: Swedish

64 pages, 2026

Note: The report is written in Swedish with a summary in English

Full text files

IHE-RAPPORT-2026_6_.pdf  Full text

Download statistics

• IHE - The Swedish Institute for Health Economics
• Home page for this series

Questions (including download problems) about the papers in this series should be directed to Annette Persson Dietmann ()
Report other problems with accessing this service to Sune Karlsson ().

RePEc:hhs:ihewps:2026_006This page generated on 2026-07-01 12:01:25.